Sight Sciences (NASDAQ:SGHT - Get Free Report) is set to post its quarterly earnings results after the market closes on Thursday, May 2nd. Analysts expect Sight Sciences to post earnings of ($0.29) per share for the quarter. Sight Sciences has set its FY 2024 guidance at EPS.Investors that wish to listen to the company's conference call can do so using this link.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings data on Thursday, March 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.13. Sight Sciences had a negative return on equity of 41.94% and a negative net margin of 68.53%. The company had revenue of $18.75 million during the quarter, compared to analysts' expectations of $18.70 million. During the same period last year, the business earned ($0.35) earnings per share. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Sight Sciences Price Performance
Shares of SGHT traded down $0.48 during trading hours on Thursday, hitting $5.14. The stock had a trading volume of 225,509 shares, compared to its average volume of 222,833. The stock has a market capitalization of $254.69 million, a price-to-earnings ratio of -4.51 and a beta of 2.83. The company has a debt-to-equity ratio of 0.26, a current ratio of 13.29 and a quick ratio of 12.65. The company's fifty day moving average is $4.94 and its two-hundred day moving average is $4.12. Sight Sciences has a 52 week low of $1.04 and a 52 week high of $11.20.
Analyst Upgrades and Downgrades
Separately, Needham & Company LLC reaffirmed a "hold" rating on shares of Sight Sciences in a research note on Wednesday, April 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $4.60.
Read Our Latest Research Report on SGHT
Insider Activity
In related news, CEO Paul Badawi sold 12,571 shares of the company's stock in a transaction dated Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total transaction of $63,860.68. Following the transaction, the chief executive officer now owns 5,750,729 shares in the company, valued at approximately $29,213,703.32. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, CEO Paul Badawi sold 12,571 shares of the firm's stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $63,860.68. Following the completion of the sale, the chief executive officer now owns 5,750,729 shares of the company's stock, valued at $29,213,703.32. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Alison Bauerlein sold 10,123 shares of the stock in a transaction on Wednesday, April 3rd. The shares were sold at an average price of $5.08, for a total value of $51,424.84. Following the completion of the transaction, the chief financial officer now owns 426,248 shares in the company, valued at $2,165,339.84. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 34,129 shares of company stock worth $173,375. 27.10% of the stock is owned by corporate insiders.
Sight Sciences Company Profile
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Stories
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
